down-arrowleft-arrowright-arrow

Andrew Roper Partner

Andrew Roper’s strong technical ability, combined with his talent for drawing out the right facts, turns seemingly difficult cases into straightforward cases.

CONTACT

EMAIL CALL

LOCATION

New York City

+1.212.588.0800

745 Fifth Avenue, 10th Floor,
New York, NY 10151

VIEW IN MAPS
  • Andrew Roper is a partner in Haug Partners’ New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets. Mr. Roper also regularly works on appellate matters before the Federal Circuit.
  • Supernus Pharms., Inc. v. TWi Pharms., Inc., 265 F. Supp. 3d 490, (trial victory aff’d Supernus Pharms. Inc. v. TWi Pharms. Inc, 2018 U.S. App. LEXIS 25271 (Fed. Cir. Sept. 6, 2018));
  • CSL Behring v Shire Viropharma Inc. 2017 Pat. App. LEXIS 13304, *1-2 (P.T.A.B. December 7, 2017) (institution denied);
  • Supernus Pharms., Inc. v. Actavis Inc., 2016 U.S. Dist. LEXIS 30444 (D.N.J. Mar. 9, 2016) (trial victory aff’d Supernus Pharms., Inc. v. Actavis Inc., 665 Fed. Appx. 901 (Fed. Cir. Dec. 12, 2016));
  • Shire LLC v. Amneal Pharms., LLC, 2014 U.S. Dist. LEXIS 85369 (D.N.J. June 23, 2014) (summary judgment victory aff’d Shire, LLC v. Amneal Pharms., LLC, 802 F.3d 1301 (Fed. Cir. 2015));
  • Otter Prods., LLC v. United States, 37 F. Supp. 3d 1306 (Ct. Int’l Trade 2014) (denying emergency motion to stay US Customs and Border Protection’s enforcement of ITC’s General Exclusion Order); Otter v. ITC and Speculative Product Design, No. 14-1480, ECF Nos. 25, 34 (Fed. Cir. 2014) (denying emergency motions to stay enforcement of US Customs and Border Protection's ITC General Exclusion Order);
  • Duramed Pharms., Inc. v. Paddock Labs., Inc., 715 F. Supp. 2d 552 (S.D.N.Y. 2010) (summary judgment victory aff’d Duramed Pharms., Inc. v. Paddock Labs., Inc., 2011 U.S. App. LEXIS 3384 (Fed. Cir. Feb. 17, 2011).
  • Case Western Reserve University, (B.S.E., Chemical Engineering, 2004)
  • University of Virginia School of Law, (J.D., 2007)
  • New York
  • Eastern District of New York
  • Southern District of New York
  • United States Court of Appeals for the Federal Circuit
  • Court of International Trade
  • Registered to practice before the U.S. Patent and Trademark Office
  • New York Intellectual Property Law Association
  • Federal Circuit Bar Association
  • Appellate Litigation
  • Biotechnology Litigation
  • Due Diligence & Investigations
  • FDA
  • Hatch-Waxman Litigation
  • Intellectual Property Litigation
  • ITC Litigation
  • Licensing & Transactions
  • Life Sciences Litigation
  • Patent Prosecution
  • PTAB Post-Issuance Proceedings

+1.212.588.0800
aroper@haugpartners.com

Related Services

  • Appellate Litigation
  • Biotechnology Litigation
  • Due Diligence & Investigations
  • FDA
  • Hatch-Waxman Litigation
  • Intellectual Property Litigation
  • ITC Litigation
  • Licensing & Transactions
  • Life Sciences Litigation
  • Patent Prosecution
  • PTAB Post-Issuance Proceedings

BAR ADMISSIONS

  • New York
  • Eastern District of New York
  • Southern District of New York
  • United States Court of Appeals for the Federal Circuit
  • Court of International Trade
  • Registered to practice before the U.S. Patent and Trademark Office

Haug Partners LLP
745 Fifth Avenue, 10th Floor,
New York, NY 10151
+1.212.588.0800
haugpartners.com

Andrew Roper

Partner

HIGHLIGHT

Andrew Roper’s strong technical ability, combined with his talent for drawing out the right facts, turns seemingly difficult cases into straightforward cases.

OVERVIEW

Andrew Roper is a partner in Haug Partners’ New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets. Mr. Roper also regularly works on appellate matters before the Federal Circuit.

REPRESENTATIVE CASES

  • Supernus Pharms., Inc. v. TWi Pharms., Inc., 265 F. Supp. 3d 490, (trial victory aff’d Supernus Pharms. Inc. v. TWi Pharms. Inc, 2018 U.S. App. LEXIS 25271 (Fed. Cir. Sept. 6, 2018));
  • CSL Behring v Shire Viropharma Inc. 2017 Pat. App. LEXIS 13304, *1-2 (P.T.A.B. December 7, 2017) (institution denied);
  • Supernus Pharms., Inc. v. Actavis Inc., 2016 U.S. Dist. LEXIS 30444 (D.N.J. Mar. 9, 2016) (trial victory aff’d Supernus Pharms., Inc. v. Actavis Inc., 665 Fed. Appx. 901 (Fed. Cir. Dec. 12, 2016));
  • Shire LLC v. Amneal Pharms., LLC, 2014 U.S. Dist. LEXIS 85369 (D.N.J. June 23, 2014) (summary judgment victory aff’d Shire, LLC v. Amneal Pharms., LLC, 802 F.3d 1301 (Fed. Cir. 2015));
  • Otter Prods., LLC v. United States, 37 F. Supp. 3d 1306 (Ct. Int’l Trade 2014) (denying emergency motion to stay US Customs and Border Protection’s enforcement of ITC’s General Exclusion Order); Otter v. ITC and Speculative Product Design, No. 14-1480, ECF Nos. 25, 34 (Fed. Cir. 2014) (denying emergency motions to stay enforcement of US Customs and Border Protection's ITC General Exclusion Order);
  • Duramed Pharms., Inc. v. Paddock Labs., Inc., 715 F. Supp. 2d 552 (S.D.N.Y. 2010) (summary judgment victory aff’d Duramed Pharms., Inc. v. Paddock Labs., Inc., 2011 U.S. App. LEXIS 3384 (Fed. Cir. Feb. 17, 2011).

EDUCATION

  • Case Western Reserve University, (B.S.E., Chemical Engineering, 2004)
  • University of Virginia School of Law, (J.D., 2007)

BAR ADMISSIONS

  • New York
  • Eastern District of New York
  • Southern District of New York
  • United States Court of Appeals for the Federal Circuit
  • Court of International Trade
  • Registered to practice before the U.S. Patent and Trademark Office

MEMBERSHIPS

  • New York Intellectual Property Law Association
  • Federal Circuit Bar Association